Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Giles

Showing results (421-430 of 503) with videos related to

Pageof 51
Sort By:
Human Mutation|July 31, 2015
Novel Homozygous Mutation of the Internal Translation Initiation Start Site of VHL is Exclusively Associated with Erythrocytosis: Indications for Distinct Functional Roles of von Hippel-Lindau Tumor Suppressor IsoformsMarije Bartels, Marieke M van der Zalm, Brigitte A van Oirschot, et al.
Scientific Reports|April 29, 2017
The centrosomal OFD1 protein interacts with the translation machinery and regulates the synthesis of specific targetsDaniela Iaconis, Maria Monti, Mario Renda, et al.
Nature Communications|December 21, 2016
Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibilityKevin Litchfield, Max Levy, Darshna Dudakia, et al.
European Urology|October 17, 2022
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines PanelUmberto Capitanio, Jens Bedke, Laurence Albiges, et al.
FEBS Letters|January 7, 2004
Fibronectin is a hypoxia-independent target of the tumor suppressor VHLHans A R Bluyssen, Martijn P J K Lolkema, Moniek van Beest, et al.
European Urology Oncology|September 26, 2024
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future DirectionsLaura Marandino, Riccardo Campi, Daniele Amparore, et al.
Journal of Medicinal Chemistry|March 23, 2001
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasationK S Jandu, V Barrett, M Brockwell, et al.
European Urology|December 11, 2017
Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal CancerThomas Powles, Laurence Albiges, Michael Staehler, et al.
Journal of Proteomics|August 3, 2018
Changes in the urinary extracellular vesicle proteome are associated with nephronophthisis-related ciliopathiesMarijn F Stokman, Irene V Bijnsdorp, Tim Schelfhorst, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2014
Murine Joubert syndrome reveals Hedgehog signaling defects as a potential therapeutic target for nephronophthisisAnn Marie Hynes, Rachel H Giles, Shalabh Srivastava, et al.
Pageof 51

Showing results (421-430 of 503) with videos related to

Sort By:
Pageof 51
Human Mutation|July 31, 2015
Novel Homozygous Mutation of the Internal Translation Initiation Start Site of VHL is Exclusively Associated with Erythrocytosis: Indications for Distinct Functional Roles of von Hippel-Lindau Tumor Suppressor IsoformsMarije Bartels, Marieke M van der Zalm, Brigitte A van Oirschot, et al.
Scientific Reports|April 29, 2017
The centrosomal OFD1 protein interacts with the translation machinery and regulates the synthesis of specific targetsDaniela Iaconis, Maria Monti, Mario Renda, et al.
Nature Communications|December 21, 2016
Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibilityKevin Litchfield, Max Levy, Darshna Dudakia, et al.
European Urology|October 17, 2022
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines PanelUmberto Capitanio, Jens Bedke, Laurence Albiges, et al.
FEBS Letters|January 7, 2004
Fibronectin is a hypoxia-independent target of the tumor suppressor VHLHans A R Bluyssen, Martijn P J K Lolkema, Moniek van Beest, et al.
European Urology Oncology|September 26, 2024
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future DirectionsLaura Marandino, Riccardo Campi, Daniele Amparore, et al.
Journal of Medicinal Chemistry|March 23, 2001
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasationK S Jandu, V Barrett, M Brockwell, et al.
European Urology|December 11, 2017
Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal CancerThomas Powles, Laurence Albiges, Michael Staehler, et al.
Journal of Proteomics|August 3, 2018
Changes in the urinary extracellular vesicle proteome are associated with nephronophthisis-related ciliopathiesMarijn F Stokman, Irene V Bijnsdorp, Tim Schelfhorst, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2014
Murine Joubert syndrome reveals Hedgehog signaling defects as a potential therapeutic target for nephronophthisisAnn Marie Hynes, Rachel H Giles, Shalabh Srivastava, et al.
Pageof 51